Form 8-K

8-K — Wave Life Sciences Ltd.

Accession: 0001193125-26-183563

Filed: 2026-04-28

Period: 2026-04-28

CIK: 0001631574

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — d135689d8k.htm (Primary)

EX-99.1 (d135689dex991.htm)

EX-99.2 (d135689dex992.htm)

GRAPHIC (g135689ex99_1p10g1.jpg)

GRAPHIC (g135689ex99_1p11g1.jpg)

GRAPHIC (g135689ex99_1p12g1.jpg)

GRAPHIC (g135689ex99_1p13g1.jpg)

GRAPHIC (g135689ex99_1p14g1.jpg)

GRAPHIC (g135689ex99_1p15g1.jpg)

GRAPHIC (g135689ex99_1p16g1.jpg)

GRAPHIC (g135689ex99_1p17g1.jpg)

GRAPHIC (g135689ex99_1p18g1.jpg)

GRAPHIC (g135689ex99_1p19g1.jpg)

GRAPHIC (g135689ex99_1p20g1.jpg)

GRAPHIC (g135689ex99_1p21g1.jpg)

GRAPHIC (g135689ex99_1p22g1.jpg)

GRAPHIC (g135689ex99_1p23g1.jpg)

GRAPHIC (g135689ex99_1p24g1.jpg)

GRAPHIC (g135689ex99_1p25g1.jpg)

GRAPHIC (g135689ex99_1p26g1.jpg)

GRAPHIC (g135689ex99_1p27g1.jpg)

GRAPHIC (g135689ex99_1p28g1.jpg)

GRAPHIC (g135689ex99_1p29g1.jpg)

GRAPHIC (g135689ex99_1p2g1.jpg)

GRAPHIC (g135689ex99_1p30g1.jpg)

GRAPHIC (g135689ex99_1p31g1.jpg)

GRAPHIC (g135689ex99_1p32g1.jpg)

GRAPHIC (g135689ex99_1p33g1.jpg)

GRAPHIC (g135689ex99_1p34g1.jpg)

GRAPHIC (g135689ex99_1p35g1.jpg)

GRAPHIC (g135689ex99_1p36g1.jpg)

GRAPHIC (g135689ex99_1p37g1.jpg)

GRAPHIC (g135689ex99_1p38g1.jpg)

GRAPHIC (g135689ex99_1p39g1.jpg)

GRAPHIC (g135689ex99_1p3g1.jpg)

GRAPHIC (g135689ex99_1p40g1.jpg)

GRAPHIC (g135689ex99_1p41g1.jpg)

GRAPHIC (g135689ex99_1p42g1.jpg)

GRAPHIC (g135689ex99_1p43g1.jpg)

GRAPHIC (g135689ex99_1p44g1.jpg)

GRAPHIC (g135689ex99_1p45g1.jpg)

GRAPHIC (g135689ex99_1p46g1.jpg)

GRAPHIC (g135689ex99_1p47g1.jpg)

GRAPHIC (g135689ex99_1p48g1.jpg)

GRAPHIC (g135689ex99_1p49g1.jpg)

GRAPHIC (g135689ex99_1p4g1.jpg)

GRAPHIC (g135689ex99_1p50g1.jpg)

GRAPHIC (g135689ex99_1p51g1.jpg)

GRAPHIC (g135689ex99_1p5g1.jpg)

GRAPHIC (g135689ex99_1p6g1.jpg)

GRAPHIC (g135689ex99_1p7g1.jpg)

GRAPHIC (g135689ex99_1p8g1.jpg)

GRAPHIC (g135689ex99_1p9g1.jpg)

GRAPHIC (g135689ex99_2p1g1.jpg)

GRAPHIC (g135689g0428082216300.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d135689d8k.htm · Sequence: 1

8-K

7 Straits View #12-00 false 0001631574 0001631574 2026-04-28 2026-04-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 28, 2026

WAVE LIFE SCIENCES LTD.

(Exact name of registrant as specified in its charter)

Singapore

001-37627

98-1356880

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

7 Straits View #12-00, Marina One

East Tower

Singapore

018936

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: +65 6236 3388

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

symbol

Name of each exchange

on which registered

$0 Par Value Ordinary Shares

WVE

The Nasdaq Global Market

Item 2.02

Results of Operations and Financial Condition.

On April 28, 2026, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 7.01

Regulation FD Disclosure.

From time to time, the Company presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On April 28, 2026, the Company updated its corporate presentation, which is available on the “Investors” section of the Company’s website at http://ir.wavelifesciences.com/. This presentation is also furnished as Exhibit 99.2 to this Current Report on Form 8-K

The information in these Items 2.02 and 7.01 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall they be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

The following exhibits relating to Items 2.02 and 7.01 are furnished and not filed:

Exhibit No.

Description

99.1

Press Release issued by Wave Life Sciences Ltd. dated April 28, 2026

99.2

Corporate Presentation of Wave Life Sciences Ltd. dated April 28, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WAVE LIFE SCIENCES LTD.

By:

/s/ Kyle Moran, CFA

Kyle Moran, CFA

Chief Financial Officer

Date: April 28, 2026

EX-99.1

Filename: d135689dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in

individuals with higher BMI, with and without type 2 diabetes, this portion of the trial remains on track to initiate in 2Q 2026

Combination and

maintenance trials of WVE-007 on track to initiate in 2026

Data from

RestorAATion-2 trial of WVE-006 (GalNAc-RNA editing) in AATD (including 400 mg monthly dose and 600 mg single dose cohorts) to be

presented at an investor webcast during the ATS International Conference in May 2026

Regulatory feedback on accelerated approval pathway for WVE-006 continues to be expected mid-2026

CTA submission for WVE-008 (GalNAc-RNA editing for PNPLA3 I148M liver disease) on track for 2026

Well capitalized with cash and cash equivalents of $544.6 million as of March 31, 2026 and expected cash runway into 3Q 2028

Investor conference call and webcast at 8:30 a.m. ET today

CAMBRIDGE, Mass., April 28, 2026 – Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on

unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.

“We’re accelerating WVE-007 to the next stages of development following the improvements in body

composition already observed in the Phase 1 portion of our INLIGHT trial, including profound reductions in harmful visceral fat, along with favorable safety and potential for once to twice yearly dosing,” said Paul Bolno, MD, MBA, President

and Chief Executive Officer at Wave Life Sciences. “This quarter, we expect to initiate the Phase 2a portion of INLIGHT in individuals with higher BMI and excess fat. Given WVE-007’s mechanism of

targeted lipolysis, we believe this portion of the study can deliver even more pronounced improvements in body composition. Importantly, we’ve designed the Phase 2a study to assess additional biomarkers of cardiometabolic health, which will

inform WVE-007’s broad potential across obesity and multiple indications, including MASH, type 2 diabetes, and cardiovascular disease. We also plan to rapidly initiate investigation of WVE-007 in both the combination and maintenance settings soon thereafter.”

Dr. Bolno added, “We

continue to make significant progress advancing our RNA editing pipeline led by WVE-006 for AATD. Clinical data from our ongoing RestorAATion-2 trial of WVE-006 has already demonstrated the potential to provide a much-needed new therapeutic option. By correcting the root cause of disease, WVE-006 restores dynamic AAT

production to address lung manifestations and lowers harmful Z-AAT to address liver manifestations of the disease, with a therapy that is well-tolerated, non-permanent,

and highly specific. WVE-006 also avoids delivery with LNPs and collateral bystander edits and indels associated with DNA base editing. In May, we expect

to highlight data from our RestorAATion-2 trial, including results from our less frequent, 400 mg monthly dose and 600 mg single dose cohorts. We remain on

track to receive regulatory feedback on a potential accelerated approval pathway for WVE-006 mid-year. Building on our clinical success in RNAi and RNA editing, we are

advancing WVE-008, as well as a pipeline of additional hepatic and extra-hepatic siRNAs and AIMers.”

Recent Business Highlights and Expected Milestones

Obesity

•

WVE-007 is an investigational GalNAc-siRNA (SpiNA design) designed

to silence INHBE mRNA to induce fat loss without muscle loss, a promising therapeutic strategy to treat obesity with strong evidence from human genetics. WVE-007 is being evaluated in the ongoing

placebo-controlled INLIGHT clinical trial.

•

Phase 1 INLIGHT: In March 2026, Wave announced interim results from the ongoing Phase 1,

single-ascending dose portion of its INLIGHT trial in healthy individuals with overweight or obesity (average BMI of ~32 kg/m2, a population with less fat and lower BMI than those in Phase 2 and

Phase 3 obesity studies), which showed further improvements in body composition at six months following a single dose of WVE-007. WVE-007 continued to be generally safe

and well tolerated. At six-month follow-up, a single 240 mg dose of WVE-007 demonstrated continued total body fat reduction (-5.3%) with muscle preservation (+2.4%), as well as clinically meaningful reductions in visceral fat (-14.3%; p<0.05) and waist circumference (-3.3%) – exceeding the 5–10% visceral fat reductions that support robust correlations to clinical outcomes (lower risk of MASH, T2D, and CVD)1.

Preservation of muscle is a key differentiator from incretin treatments and is linked to health benefits including higher basal metabolic rate, improved insulin sensitivity, and prevention of weight regain. Activin E reductions were robust and

durable and continue to support potential for once or twice-yearly dosing.

•

Additional data from INLIGHT, including data from the 600 mg Phase 1 SAD cohort, are expected in 2026.

•

Phase 2a INLIGHT: The U.S. Food and Drug Administration (FDA) has accepted the Phase 2a multidose portion

of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI (35-50 kg/m2) with and without type

2 diabetes. This placebo-controlled (3:1) portion of the trial will include multiple assessments over a 12-month period, including body weight, waist circumference, body composition (MRI and DEXA), liver fat (MRI-PDFF), HbA1c, lipid levels, CRP, and muscle function, with a first assessment at three months following the first dose. Data from the Phase 2a study will inform further development of WVE-007 in obesity, as well as in MASH, type 2 diabetes, and cardiovascular disease.

•

Wave is on track to initiate the Phase 2a portion of INLIGHT in the second quarter of 2026.

•

Combination with incretin and post-incretin maintenance studies of

WVE-007 are expected to initiate in 2026.

AATD

(Alpha-1 antitrypsin deficiency)

•

WVE-006 is an investigational GalNAc-conjugated, subcutaneously

delivered, RNA editing oligonucleotide (AIMer) for AATD. The RestorAATion-2 clinical trial is fully enrolled through the 600 mg cohort, and dosing is complete in the single dose portion.

•

Clinical data from the 200 mg (single and biweekly) and 400 mg (single dose) cohorts of the ongoing RestorAATion-2 clinical trial have demonstrated WVE-006 achieved key AATD treatment goals by recapitulating an MZ-like phenotype,

characterized by basal AAT levels above 11 µM, wild-type M-AAT above 50% of total AAT, reduction of Z-AAT protein, and dynamic AAT production during an acute phase

response. These data will be included at multiple upcoming medical meetings including in a late-breaking oral presentation at the American Thoracic Society (ATS) International Conference

(Dr. Kenneth R. Chapman, MsC, MD, FRCPC, FACP, FERS, Department of Medicine, University of Toronto) on May 18, 2026 and in an oral presentation at the European Association for the Study of the Liver (EASL) Congress (Dr. Pavel

Strnad, MD, Professor of Translational Gastroenterology and Senior Physician at the University Hospital Aachen, Department of Medicine III) on May 29, 2026.

•

Wave will hold an investor conference call and webcast at 5:30 p.m. ET on May 18, 2026 to highlight its AATD

program, including new clinical data from the 400 mg multidose cohort and 600 mg single dose cohort of RestorAATion-2. Wave also expects to share data from the 600 mg multidose cohort in the second half of

2026.

•

Wave expects to receive regulatory feedback on a potential accelerated approval pathway mid-2026.

PNPLA3 I148M liver disease

•

WVE-008: Wave is building on its clinical success in RNA editing

by advancing WVE-008, a GalNAc-conjugated AIMer for homozygous PNPLA3 I148M liver disease.

•

Wave will highlight preclinical data supporting WVE-008 in a poster

presentation at the EASL Congress.

•

Clinical trial application (CTA) filing for WVE-008 is on track for 2026.

DMD (exon 53)

•

WVE-N531: Wave remains on track to file a New Drug Application

(NDA) in 2026 to support accelerated approval of WVE-N531 with monthly dosing.

Bifunctional

modality

•

Wave is applying learnings from across its platform and chemistry optimization to investigate new bifunctional

modalities which combine RNAi and RNA editing or dual RNAi silencing into a single oligonucleotide construct. These constructs are designed to silence multiple targets or silence one target while simultaneously editing or upregulating another

distinct target. Wave expects to provide further updates on its bifunctional modality in 2026.

Financial Highlights

•

Cash and cash equivalents were $544.6 million as of March 31, 2026, compared to $602.1 million as

of December 31, 2025. Wave expects that its current cash and cash equivalents will be sufficient to fund operations into the third quarter of 2028. Potential future milestone and other payments to Wave under its GSK collaboration are not

included in its cash runway.

•

Revenue recognized was $38.2 million for the first quarter of 2026 as compared to $9.2 million in the

prior year quarter.

•

Research and development expenses were $47.4 million in the first quarter of 2026 as compared to

$40.6 million in the same period in 2025.

•

General and administrative expenses were $22.1 million in the first quarter of 2026 as compared to

$18.4 million in the same period in 2025.

•

Net loss was $26.1 million for the first quarter of 2026 as compared to a net loss of $46.9 million in

the prior year quarter.

Investor Conference Call and Webcast

Wave will host an investor conference call today at 8:30 a.m. ET to review the first quarter 2026 financial results and pipeline updates. A webcast of the

conference call can be accessed by visiting “Investor Events” on the investor relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during

the Q&A portion of the live call can join the conference call at the audio-conferencing link here. Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life Sciences

Wave Life

Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®,

combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities,

including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008)

programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to

“Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science,

pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, concerning our

goals, beliefs, expectations, strategies, objectives and plans, and other statements that are not necessarily based on historical facts, including statements regarding the following, among others: the anticipated initiation, timing, design,

progress, data and announcements related to our clinical trials, including interactions with and feedback from regulators and any potential registrational submissions based on these data; the future performance and results of our programs in

clinical trials, including the anticipated therapeutic benefits of such programs, and our expectations with respect to how our clinical data may predict success for our future therapeutic candidates and data readouts; the potential commercialization

of our programs the potential size of the markets that our therapeutics may address; preclinical activities and programs and their potential to transition into clinical-stage programs, and the timing, progress and announcement of such events; the

progress and potential benefits, including the potential achievement of milestones, of collaborations and strategic partnerships; the expected benefits of our stereopure oligonucleotides compared with stereorandom oligonucleotides; the breadth and

versatility of our PRISM® drug discovery and development platform; the potential benefits of our RNA-targeting modalities, including RNAi (SpiNA), RNA editing (AIMers), and our bifunctional

modalities; the potential for certain of our programs to be best-in-class or

first-in-class, or to change the existing treatment paradigm or show substantial benefits over existing standards of care; our financial performance, including the

anticipated duration of our cash runway and our ability to fund future operations; our intended uses of capital; and our expectations regarding the impact of any potential global macro events on our business. The words “may,”

“will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,”

“project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual results to differ materially from

those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the clinical results and timing of our programs, which may not support further development of our

product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; our effectiveness in managing current and future clinical trials and regulatory processes; the continued development and

acceptance of nucleic acid therapeutics as a class of drugs; our ability to demonstrate the therapeutic benefits of our stereopure candidates in clinical trials, including our ability to develop candidates across multiple therapeutic modalities; our

ability to obtain, maintain and protect intellectual property; our ability to fund our operations and to raise additional capital as needed; competition from others developing therapies for similar uses; and any impacts on our business as a result

of or related to any global economic uncertainty or market disruptions, as well as the other risks and uncertainties described in the section entitled “Risk Factors” in our most recent Annual Report on Form

10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings we make with the SEC from time to time. In addition, any forward-looking statements represent our views only as of

today and should not be relied upon as representing our views as of any subsequent date. We undertake no obligation, except to the extent required by law, to update the information contained in this press release to reflect subsequently occurring

events or circumstances.

Contact:

Kate Rausch

VP, Corporate Affairs and Investor Relations

+1 617-949-4827

Investors:

James Salierno

Director, Investor Relations

617-949-4043

InvestorRelations@wavelifesci.com

Media:

Katie Sullivan

Senior Director, Corporate Communications

+1 617-949-2936

MediaRelations@wavelifesci.com

Gabriely et al., Diabetes 2002; Campos et al., Diabetes & Vascular Disease Research 2019; Huang et

al., Front Endocrinol 2023.; Cesaro et al., Front Cardiovasc Med 2023; Khawaja et, al., Curr Cardiol Rep 2024; Hiuge-Shimizu et al., J Atheroscler Thromb 2011.; Liao et al., PLoS ONE 2023; Jung et al., Endocrinol Metab 2020; Hanlon & Yuan,

Clin Liver Dis 2021.; Liao et al., PLoS ONE 2023; Jung et al., Endocrinol Metab 2020

WAVE LIFE SCIENCES LTD.

UNAUDITED CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

March 31, 2026

December 31, 2025

Assets

Current assets:

Cash and cash equivalents

544,591

602,068

Accounts receivable

—

1,276

Prepaid expenses

13,225

8,395

Other current assets

3,456

3,075

Total current assets

561,272

614,814

Long-term assets:

Property and equipment, net of accumulated depreciation of $50,352 and $49,522 as of

March 31, 2026 and December 31, 2025, respectively

7,077

7,405

Operating lease

right-of-use assets

10,994

12,458

Restricted cash

3,815

3,806

Other assets

386

Total long-term assets

22,272

23,685

Total assets

583,544

638,499

Liabilities, Series A preferred shares, and shareholders’ equity

Current liabilities:

Accounts payable

19,064

15,700

Accrued expenses and other current liabilities

13,043

26,564

Current portion of deferred revenue

9,396

44,440

Current portion of operating lease liability

8,328

8,361

Total current liabilities

49,831

95,065

Long-term liabilities:

Deferred revenue, net of current portion

14,596

7,798

Operating lease liability, net of current portion

7,387

9,405

Total long-term liabilities

21,983

17,203

Total liabilities

71,814

112,268

Series A preferred shares, no par value; nil and 3,901,348 shares issued and outstanding at

March 31, 2026 and December 31, 2025, respectively

—

7,874

Shareholders’ equity:

Ordinary shares, no par value; 192,337,566 and 187,660,263 shares issued and outstanding at

March 31, 2026 and December 31, 2025, respectively

1,626,879

1,616,478

Additional paid-in capital

237,428

228,365

Accumulated other comprehensive loss

(254

)

(250

)

Accumulated deficit

(1,352,323

)

(1,326,236

)

Total shareholders’ equity

511,730

518,357

Total liabilities, Series A preferred shares, and shareholders’ equity

583,544

638,499

The accompanying notes are an integral part of the consolidated financial statements.

WAVE LIFE SCIENCES LTD.

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

Three Months Ended March 31,

2026

2025

Revenue

38,246

9,175

Operating expenses:

Research and development

47,440

40,622

General and administrative

22,104

18,357

Total operating expenses

69,544

58,979

Loss from operations

(31,298

)

(49,804

)

Other income, net:

Interest income

5,291

2,875

Other income (expense), net

(80

)

Total other income, net

5,211

2,926

Loss before income taxes

(26,087

)

(46,878

)

Income tax benefit

—

Net loss

(26,087

)

(46,878

)

Net loss per share attributable to ordinary shareholders—basic and diluted

(0.13

)

(0.29

)

Weighted-average ordinary shares used in computing net loss per share attributable to ordinary

shareholders—basic and diluted

200,167,869

162,572,026

Other comprehensive income (loss):

Net loss

(26,087

)

(46,878

)

Foreign currency translation gain (loss)

)

Comprehensive loss

(26,091

)

(46,820

)

The accompanying notes are an integral part of the consolidated financial statements.

EX-99.2

Filename: d135689dex992.htm · Sequence: 3

EX-99.2

Exhibit 99.2 Wave Life Sciences Corporate Presentation April 28,

2026

Forward-looking statements This document contains forward-looking

statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and

development plans, collaborations and partnerships, regulatory activities and timing thereof, competitive position, potential growth opportunities, use of proceeds and the effects of competition are forward-looking statements. These statements

involve known and unknown risks, uncertainties and other important factors that may cause the actual results, performance or achievements of Wave Life Sciences Ltd. (the “Company”) to be materially different from any future results,

performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,”

“plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,”

“potential” or “continue” or the negative of these terms or other similar expressions. The forward- looking statements in this presentation are only predictions. The Company has based these forward-looking statements largely

on its current expectations and projections about future events and financial trends that it believes may affect the Company’s business, financial condition and results of operations. These forward-looking statements speak only as of the date

of this presentation and are subject to a number of risks, uncertainties and assumptions, including those listed under Risk Factors in the Company’s Form 10-K and other filings with the SEC, some of which cannot be predicted or quantified and

some of which are beyond the Company’s control. The events and circumstances reflected in the Company’s forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the

forward-looking statements. Moreover, the Company operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that

the Company may face. Except as required by applicable law, the Company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or

otherwise. 2

Our Mission To unlock the broad potential of RNA medicines to transform

human health 3

Building a leading RNA medicines company Differentiated RNA medicines

Translating genetic insights into Unlocking platform and chemistry potentially best-in-class medicines emerging pipeline RNAi WVE-007 (obesity) • Extra-hepatic capabilities: • Differentiated mechanism with RNAi and RNA editing focused on

fat loss and • Proprietary chemistry muscle preservation • Leveraging deep insights in human RNA editing WVE-006 (AATD) • Bifunctional modalities: genetics WVE-008 (liver disease) single oligonucleotide constructs for dual RNAi

• Restoration of functional • Strong and broad IP silencing or RNAi silencing + protein production RNA editing • In-house GMP manufacturing Other modalities: Splicing, antisense silencing Well capitalized with expected cash runway

into 3Q 2028 4

For over a decade Wave has been extending the frontiers of RNA therapies

delivering breakthroughs in nucleic acid chemistry RNAi — SpiNA RNA editing — AIMer Protein reduction Ago2 loading 100% 80% 60% 40% 20% 0% C C N3U N3U Base 2’ deoxy 2’ OMe 2’ deoxy 2’ OMe Sugar Substantial

improvements in potency, duration of activity, and Ago2 loading Increased RNA editing efficiency achieved with Wave’s proprietary SpiNA design with proprietary chemistry Proprietary chemistry has dramatically increased potency and durability 5

SpiNA: Stereopure interfering Nucleic Acid https://wavelifesciences.com/science/publications/ % Ugp2 mRNA editing

Robust RNA medicines pipeline with first-in-class RNAi and RNA editing

programs Patient population Program Discovery IND / CTA Enabling Studies Clinical (US & Europe) R N A i ( S p i N A ) 175M WVE-007 (GalNAc) INHBE (obesity) (>1 billion globally) GalNAc / extra-hepatic -- Multiple R N A E D I T I N G ( A I M e

r ) WVE-006 (GalNAc) 200K SERPINA1 (AATD) WVE-008 (GalNAc) 9M PNPLA3 (liver disease) GalNAc / extra-hepatic -- Multiple S PLI C I N G WVE-N531 2.3K Exon 53 (DMD) Other exons (DMD) Up to 18K A LLE LE - S E LE C T I V E S I LE N C I N G WVE-003 25K

Symptomatic (SNP3) mHTT (HD) 60K Pre-Symptomatic (SNP3) 6 AATD: Alpha-1 antitrypsin deficiency; DMD: Duchenne muscular dystrophy; HD: Huntington’s disease

WVE-007 GalNAc-siRNA silencing Obesity 7

WVE-007 (investigational INHBE GalNAc-siRNA) is a potentially

transformative approach for the > 1 billion people living with obesity globally Significant unmet need in obesity WVE-007 Focused on adipocyte lipolysis and Current standard of care: Focused on caloric restriction by reducing appetite and slowing

gastric emptying not caloric deficit Incretins limited by: Drives total and visceral fat loss ✓ 1 Muscle loss X 2 X Frequent dosing Preserves muscle ✓ 3 Poor tolerability X 4,5 High discontinuation rates X Potential 1–2x per year

dosing ✓ Resulting in need for therapies that can: ✓ Generally safe and well tolerated • Induce fat loss with muscle preservation • Leverage orthogonal mechanism for enhanced efficacy and maintain metabolic improvements

after incretin cessation 8 1. Sargeant, et al. 2019 Endocrinol Metab (Seoul) 34, 247; 2. Wegovy PI; 3. Ghusn and Hurtado. 2024 Obesity Pillars 12, 100127; 4. Leach, et al. 2023 Prime Therapeutics Claims Analysis; 5. Gasoyan, et al. 2024 Obesity

(Silver Spring) 32, 486.

Human genetic data demonstrate that heterozygous INHBE loss-of-function

(LoF) carriers have lower visceral fat and a healthier metabolic profile Heterozygous INHBE LoF carriers versus non-carriers: Favorable traits : Waist-to-hip ratio✓ Lower abdominal obesity Visceral adipose volume by MRI ✓ Reduced

visceral fat Serum triglycerides ✓ Lower triglycerides HDL-c ✓ Higher “good” cholesterol ApoB ✓ Lower ApoB %HbA1c✓ Improved glucose control Liver cT1 by MRI ✓ Less liver inflammation/fibrosis ALT

✓ Less liver damage Standard deviations -0.4 -0.2 0 0.2 0.4 Type 2 diabetes ✓ Lower risk of type 2 diabetes Coronary heart disease ✓ Lower risk of CHD Odds ratio 0.50 0.75 1 1.5 2.0 9 Akbari et al. Nat Commun. 2022 Aug

23;13(1):4844; Deaton et al. Nat Commun. 2022 Jul 27;13(1):4319. Waist-to-hip ratio, BMI-adjusted: Visceral adipose volume (MRI), BMI adjusted; HDL-c: high-density lipoprotein cholesterol; %HbA1c: glycated hemoglobin; ALT: alanine transaminase;

ApoB: apolipoprotein B; CHD: coronary heart disease; cT1: corrected T1

Silencing INHBE mRNA has the potential to treat obesity and associated

metabolic diseases Release of dimerized Binds to and activates ACVR1C Block adipose INHBE subunits creates (ALK7) receptor in adipose tissue lipolysis hepatokine Activin E Activin E Activin E Increased abdominal adiposity leads to obesity, I II I I

CVD and T2D Adipocyte ALK7 Decreased abdominal adiposity leads to weight loss and reduced risk for CVD and T2D Reduction of Reduced release of Diminished activation of Increased adipose INHBE mRNA with hepatokine Activin E ACVR1C (ALK7) receptor in

lipolysis and shrink GalNAc-siRNA adipose tissue adipocytes 10 1. Cell Reports (2018) 25, 1193–1203; 2. Biochemical Journal (2024) 481 547–564; 3. PNAS 2023 Vol. 120 No. 32 e2309967120; 4. Nat Commun 2022. https://doi.org/10.1038/s41467-

022-32398-7; 5. Nat Commun 2022. https://doi.org/10.1038/s41467-022-31757-8

Higher circulating Activin E levels are correlated with higher BMI,

higher abdominal fat, and higher fasting insulin in non-diabetic adults BMI Fasting Insulin Abdominal Fat Further supports INHBE suppression as a weight loss approach for individuals living with obesity 11 Dubey et al. Activin E levels correlate

with indicators of metabolic dysfunction in humans. ObesityWeek 2025.

WVE-007 is designed to improve body composition by decreasing fat and

preserving muscle Total Fat REDUCED Subcutaneous fat Visceral Fat REDUCED Visceral fat Muscle Muscle PRESERVED 12

WVE-007’s mechanism is focused on lipolysis and directly reducing

visceral and subcutaneous fat Visceral fat drives insulin resistance and Reduced visceral fat is associated with many cardiometabolic disorders multiple health benefits Visceral fat decrease • MASH ≥ 5% 1 Improved insulin sensitivity :

Lower HbA1c and better • Type 2 lipid profile diabetes ≥ 5-10% • Cardiovascular 2 Reduced cardiovascular risk : Reduced blood pressure, improved lipids, lower systemic inflammation diseases ≥ 10% • PCOS Visceral fat 3

Reduced liver fat (steatosis) : Significant reduction in hepatic triglycerides, improved liver enzymes Waist circumference is a 4 Decreased hepatic fibrosis : Resolution of steatohepatitis clinical proxy for visceral fat in up to 90%, fibrosis

regression in many cases 13 1. Gabriely et al., Diabetes 2002; Campos et al., Diabetes & Vascular Disease Research 2019; Huang et al., Front Endocrinol 2023. 2. Cesaro et al., Front Cardiovasc Med 2023; Khawaja et al., Curr Cardiol Rep 2024;

Hiuge-Shimizu et al., J Atheroscler Thromb 2011. 3. Liao et al., PLoS ONE 2023; Jung et al., Endocrinol Metab 2020; Hanlon & Yuan, Clin Liver Dis 2021. 4. Liao et al., PLoS ONE 2023; Jung et al., Endocrinol Metab 2020

WVE-007 aims to address a key limitation of current standard of care:

up to 40% of weight loss is driven by muscle loss Preservation of muscle mass is linked to many health benefits 5,6 • Higher basal metabolic rate • Reduced visceral fat 1 (BMR) 7,8 • Prevent weight regain 2,3 • Improved

insulin sensitivity • Improved glucose 2,3 • Increased caloric expenditure homeostasis 1 post-exercise • Increased bone density, • Preserve muscle strength and strength, function, and 4 9,10 function longevity 14 1. J. Clin.

Med. 2024, 13, 5862; 2. J. Diab. Res. 2017, 8314852; 3. J. Funct. Morphol. Kinesiol. 2025, 10, 244; 4. J Bone Mineral Res. 2018, 33(2): 211–220; 5. Front. Nutr. 2023, 10:1246157; 6. Nat. Med. 2026, 32: 869–882; 7. Med Sci Sports Exerc.

2022, 54(12):2031-2036; 8. The Lancet eClinical Medicine, 2024, 69: 102475; 9. Ann Geriatr Med Res 2025, 29(1):1-14; 10. Age and Ageing, 2025, 54(7): afaf189; 11. Sargeant, et al. 2019 Endocrinol Metab (Seoul) 34, 247.

A single dose of INHBE GalNAc-siRNA led to shrinkage of adipocytes in

DIO mice Mean adipocyte diameter DIO Lean PBS INHBE GalNAc-siRNA (μm) ✱✱✱ 80 60 40 20 0 Lean DIO DIO PBS INHBE GalNAc- siRNA 15 Data presented at ADA Scientific Sessions June 2025 ***p<0.001; Day 28

A single dose of INHBE siRNA led to a lower inflammatory state of

visceral adipose tissues in DIO mice, with strong suppression of pro-inflammatory M1 macrophages in visceral fat Macrophages (Mᶲ) (F4/80) Pro-inflammatory (M1) Mᶲ Anti-inflammatory (M2) Mᶲ (CD11c) (CD163) INHBE GalNAc siRNA INHBE

GalNAc siRNA INHBE GalNAc siRNA PBS 3 mg/kg 10 mg/kg PBS 3 mg/kg 10 mg/kg PBS 3 mg/kg 10 mg/kg ✱ 1.0 0.8 0.6 0.4 0.2 0.0 PBS 3 mg/kg 10 mg/kg PBS 3 mg/kg 10 mg/kg PBS 3 mg/kg 10 mg/kg 16 Data presented at ADA Scientific Sessions June 2025

***p<0.001, *p<0.05, ns=non-significant %F4/80 positive area

Lowering of inflammatory state of epiWAT visceral fat induced by single

dose of INHBE siRNA resulted in 58% reduction of adipose fibrosis Reduced staining illustrates decreased tissue fibrosis Fibrosis in mouse adipose (Day 56) 10 mg/kg PBS 3 mg/kg ✱ 15 10 5 0 PBS 3 mg/kg 10 mg/kg 17 Data are means ± SEM of

6 mice. Each dot represents an individual mouse. Kruska-Wallis test with Dunn’s multiple comparisons. *P<0.05 Trichrome % Trichrome positive area

Treatment with WVE-007 (investigational INHBE GalNAc-siRNA) is expected

to drive fat reduction and improve key measures of cardiometabolic health 1 Driving fat reduction And improving clinical outcomes Leading siRNA design (SpiNA) WVE-007 Reduction of INHBE mRNA and (INHBE GalNAc-siRNA) circulating Activin E

Proprietary, Cardiometabolic clinically validated ✓ outcomes chemistry Adipocyte Adipocyte lipolysis size Risk of CVD Subcutaneous delivery Insulin ✓ (GalNAc) Risk of T2D sensitivity Proinflammatory macrophages Potential for infrequent

✓ dosing (1 – 2x year) Fibrosis 18 1. SpiNA design is derived from Liu et al., 2023 Nucleic Acids Research doi: 10.1093/nar/gkad268

Single dose of INHBE GalNAc-siRNA led to durable Activin E reductions,

and sustained improvements in body composition in DIO mice Muscle Durable Activin E Reduction in fat Reduction in body weight ✓ ✓ ✓ preservation ✓ reduction Serum Activin E Epididymal fat weight Quadricep weight Single

dose INHBE GalNAc-siRNA * 0.25 150 -23% 0.75 0.20 -40% INHBE siRNA 100 0.15 0.50 0.10 50 0.25 Semaglutide 0.05 0 0.00 0.00 PBS INHBE INHBE INHBE PBS Sema- PBS INHBE INHBE 10 mg/kg 3 mg/kg 3 mg/kg 10 mg/kg glutide 10 mg/kg 19 Left and right panels:

Semaglutide 10 nmol/kg daily SC in mouse is equivalent to therapeutic dose of 2.4mg weekly SC in human; INHBE GalNAc-siRNA 10 mg/kg dose. All data from preclinical studies were conducted in mice fed with 60% high fat diet. Linear Mixed Effects ANOVA

with post hoc comparisons of marginal treatment effects vs. PBS per tissue.* p < 0.05 Activin E (%Control) Tissue weight (g) Tissue weight (g)

WVE-007 has potential for use synergistically with GLP-1s or to curtail

weight regain after the cessation of treatment with GLP-1, based on preclinical data Combined with GLP-1: Greater weight loss After cessation of GLP-1: Curtails weight regain ✓ ✓ p<0.05 ~2x greater weight loss Not significant Day

Day Single dose INHBE GalNAc-siRNA Daily GLP-1 PBS Daily GLP-1 Semaglutide Semaglutide Control for Semaglutide INHBE GalNAc-siRNA Dose INHBE GalNAc-siRNA Semaglutide + Control for siRNA Semaglutide + INHBE GalNAc-siRNA INHBE GalNAc-siRNA 20 Data

from preclinical studies conducted in mice fed with 60% high fat diet; Left: semaglutide10 nmol/kg daily SC in mouse is equivalent to therapeutic dose of 2.4mg weekly SC in human. Left Stats: Linear Mixed Effects ANOVA with post hoc comparisons of

marginal treatment effects of Semaglutide vs. Semaglutide + INHBE GalNAc-siRNA per time point * p < 0.05; Right Stats: Linear Mixed Effects ANOVA with post hoc comparison of Day 28 vs. Day 56 marginal effects per treatment Difference in body

weight (% of PBS, same time point)

Phase 1 portion of INLIGHT trial is investigating WVE-007 in

individuals living with overweight or obesity, otherwise healthy Phase 1 lower BMI (SAD) Phase 2a high BMI (MAD) • Average BMI: 32 kg/m² SAD Cohort 4 MAD high BMI (35–50 kg/m²)+T2D cohorts 600 mg (n=32) • HbA1c: <5.9%

• Otherwise healthy SAD Cohort 3 MAD high BMI (35–50 kg/m²) cohorts • Assessments include: 400 mg (n=32) Safety and tolerability, PK, Activin E, body • Individuals with higher BMI with and without type 2 diabetes SAD

Cohort 2 composition (DEXA), 240 mg (n=32) • Assessments to additionally include: biomarkers, body weight – Body composition (MRI in addition to DEXA) • No diet or exercise SAD Cohort 1 – Liver fat (MRI-PDFF) modifications 75

mg (n=8) PK/PD and safety only (no DEXA) • Diet and exercise modifications included Evaluate safety, tolerability, and PK; assess metabolic and body composition Evaluate safety, tolerability, and PK improvements as well as weight loss 21 SAD:

single-ascending dose; MAD: multi-ascending dose; PK: pharmacokinetics. Average BMI of 75 mg, 240 mg, and 400 mg cohorts.

Clinically meaningful improvements in body composition at six months

following a single dose of WVE-007 Phase 1 otherwise healthy (SAD) Lower BMI of ~32 kg/m² Activin E change in INLIGHT Improved body composition six months following single 240 mg dose: * - Significant reduction in visceral fat (-14% ) -

Reduction in waist circumference (-3%) - Reduction in total fat (-5%) - Stabilization of lean mass (+2%) - Reduction in body weight (-1%) • 400 mg three-month data emphasize impact of baseline body composition on therapeutic effect •

Durable and dose-dependent suppression of Single dose WVE-007 (GalNAc-siRNA) Activin E sustained through at least 7 months continues to support 1-2x yearly dosing Dose Placebo (N=26) WVE-007 75 mg (N=6) WVE-007 240 mg (N=24) • Generally safe

and well tolerated WVE-007 400 mg (N=24) WVE-007 600 mg (N=24) Durability of suppression continues to support dosing WVE-007 once or twice per year 22 INLIGHT interim Phase 1 data reported March 26, 2026; Left: figure shows sample means and SEMs.

All MMRM baseline and placebo comparisons from Day 8 onwards are p<0.003. Right: *p<0.05. All reductions are placebo-adjusted % change from baseline were estimated using an MMRM model with fixed effects for treatment group, visit,

treatment-by-visit interaction, and baseline as a covariate; estimates were based on geometric mean ratios.

Single dose of WVE-007 in a lower BMI population led to greater

improvement in body composition by VMR versus semaglutide Visceral Fat-to-Muscle 4 Improvement in body composition by VMR at 3 months and 6 months Ratio (VMR) • Established measure of body BELIEVE Phase 2 Trial 2 2 composition integrating

harmful BMI: ~32 kg/m BMI: ~37 kg/m visceral fat and beneficial lean WVE-007 Semaglutide Semaglutide Bimagrumab mass in a single index Single dose Weekly Weekly 2-3 doses 3 months 240 mg 1.0 mg 2.4 mg 10 mg/kg 0% • Lower VMR is associated with

0.0% decreased risk of MASH / -2.6% -5% 1,2 3 MAFLD, type 2 diabetes, and -10% -8.3% cardiometabolic disorders (e.g., -9.6% 1,3 dyslipidemia, hypertension) 6 months 0% -5% -10% -8.8% -12.2% -15% -16.5% -20% -18.8% 1. Zhang S, et al. 2023 Diabetes

Metab Res Rev. 39(2):e3597; 2. Liu C, et al. 2024 Lipids Health Dis. 23(1):104; 3. Wang Q, et al. 2019 Diabetes Metab Syndr Obes. 12:1399-1407. 4. Placebo- 23 corrected VMR calculated based on changes from baseline in visceral fat and lean mass at 3

and 6 mo. For BELIEVE, values are from Heymsfield SB, et al. 2026 Nat Med 32, 869–882. Note: The data presented above are derived from different clinical trials with differences in trial design and patient population, including with respect to

BMI. As a result, cross-trial comparisons cannot be made and no head-to-head clinical trials have been conducted. Placebo-adjusted % difference from baseline in VMR Improvement Improvement

INLIGHT Phase 2a: higher BMI population aligns with Phase 2 and 3

obesity trials, potential for continued improvements in body composition Total fat and BMI at baseline Visceral fat and BMI at baseline Phase 2 BELIEVE baseline Phase 2 BELIEVE baseline 50 1.75 (semaglutide and / or bimagrumab) (semaglutide and / or

bimagrumab) Phase 2a Phase 2a BMI (35-50 BMI (35-50 2 2 1.50 kg/m ) kg/m ) 40 240 mg WVE-007 1.25 Phase 1 (baseline) BELIEVE Phase 2 study Baseline (by cohort) 400 mg WVE-007 1.00 240 mg WVE-007 Phase 1 (baseline) 30 Week 48 (by cohort) Phase 1

(baseline) 0.75 US population data from 400 mg WVE-007 NHANES (VAT and BMI) Phase 1 (baseline) 20 0.50 50% of population 95% of population 0.25 10 0.00 15 20 25 30 35 40 45 15 20 25 30 35 40 45 2 2 BMI (kg/m ) BMI (kg/m ) Expect greater fat loss in

INLIGHT Phase 2a in participants with more excess fat 24 NHANES population reference: Adults aged 20–59 with valid DXA-derived visceral adipose tissue measurements, pooled across 2011–2018 survey cycles (n = 11,934). VAT mass (kg)

estimated from DXA (Hologic); BMI from measured height and weight. Contours represent 2D kernel density estimates of the cross-sectional population distribution. Clinical trial data overlaid as change from baseline within the NHANES VAT–BMI

coordinate space. BELIEVE data points from Heymsfield SB, et al. 2026 Nat Med 32, 869–882. Total Body Fat Mass (kg) Visceral Adipose Tissue (kg)

High BMI Phase 2a (MAD) global, placebo-controlled study will inform

further development in obesity, as well as MASH, type 2 diabetes, and CVD High BMI • Individuals with higher BMI 2 D1 D85 (35–50 kg/m ) and comorbidities Cohort 1 N=40 (3:1) 240 mg• Assessments include: • Body weight D1 D85

• Body composition Cohort 2 N=40 (3:1) (MRI in addition to DEXA) 400 mg • Liver fat (MRI-PDFF) High BMI + T2D • HbA1c, lipid levels, CRP D1 D85 • Muscle function Cohort 1 N=40 (3:1) • Diet and exercise modifications 240

mg included D1 D85 Cohort 2 • 12-month study duration N=40 (3:1) 400 mg • First assessment Day 85 (3 months) Expect to initiate high BMI Phase 2a (MAD) portion of INLIGHT in 2Q 2026 25 SAD: single-ascending dose; MAD: multi-ascending

dose; PK: pharmacokinetics; MASH: metabolic dysfunction-associated steatohepatitis; CVD: cardiovascular disease

On track to initiate the Phase 2a portion of INLIGHT in 2Q 2026;

combination and maintenance studies of WVE-007 expected to initiate in 2026 Monotherapy Combination Maintenance Single agent in individuals Add-on to incretin An off-ramp post-incretin living with obesity treatments treatments • To induce fat

loss with muscle • To leverage an orthogonal • To prevent weight regain and preservation and favorable mechanism to incretins for maintain metabolic safety and tolerability enhanced efficacy improvements upon incretin cessation Potential

to address more than one billion individuals with obesity globally 26 Phelps, NH, et al. 2024 Lancet 403, 1027

INHBE silencing provides opportunity to address additional significant

indications through lowering of visceral fat Obesity ~110M PCOS ~9M Visceral fat reductions Cardiovascular disease Type 2 diabetes ~20M ~38M MASH ~23M Therapeutic indications and US patient populations 27 PCOS, polycystic ovary syndrome 1. All

prevalence are US estimates. Prevalence of obesity, type 2 diabetes, and cardiovascular disease based on CDC / NHANES figures. MASH prevalence estimated from Estes, C. et al. 2018 Hepatology 67, 123. PCOS prevalence based on WHO

estimates.

WVE-006 RNA editing (AIMer) Alpha-1 antitrypsin deficiency (AATD)

AATD impacts multiple organ systems and has limited treatment options

• AATD is a rare, inherited genetic disorder that is commonly caused by a G-to-A point mutation in the SERPINA1 gene • Pi*ZZ genotype is leading cause of severe AATD, predisposing to progressive lung damage, liver damage or both •

Aggregation of mutant Z-AAT protein in hepatocytes and a lack of functional, wild-type M-AAT drives liver and lung disease, respectively AATD Lung Disease AATD Liver Disease • Treatment goal: Minimize episodic • Treatment goal: Decrease

Emphysema Hepatocellular Fibrosis → Cirrhosis → Carcinoma Bronchiectasis exacerbations and associated damage Z-AAT protein • Lung damage occurs during • Progressive liver disease exacerbations that induce an results from

Z-AAT-induced inflammatory acute phase response, proteotoxic stress when more AAT protein is needed for protection • Weekly IV augmentation therapy is only treatment option• No approved therapies — No protective increase in AAT

protein levels during acute phase response without additional IV infusions ~200K people in the US and Europe are homozygous for the Z allele (Pi*ZZ genotype) 29 Strnad et al., 2020 N Engl J Med 382:1443-55; Blanco et al. 2017 Int J Chron Obstruct

Pulmon Dis 12:561-69

WVE-006: Potential first-in-class, convenient therapy for AATD that

addresses both liver and lung manifestations of the disease WVE-006 Restore circulating M-AAT 1 2 Reduce Z-AAT protein (RNA editing) and physiological AAT ✓ ✓ aggregation in liver protein production Proprietary ✓ chemistry

Highly specific ✓ Z-AAT (no bystanders) Subcutaneous ✓ M-AAT delivery (GalNAc) RNA correction replaces mutant M-AAT reaches lungs to protect Z-AAT protein with wild-type M-AAT Infrequent dosing from proteases and reduce risk of protein

to reduce risk of liver ✓ lung pathology pathology 30 Strnad et al., 2020 N Engl J Med 382:1443-55; Stoller et al., 1993 Alpha-1 Antitrypsin Deficiency GeneReviews. M-AAT: Wild-type alpha-1 antitrypsin protein Z-AAT: mutant alpha-1

antitrypsin protein

RNA editing aims to increase M-AAT and restore physiological AAT

production during acute phase response Genotype Null Pi*ZZ Pi*MZ Pi*MM No AAT protein 100% Z-AAT Z-AAT and M-AAT 100% M-AAT AAT levels increase during No No Yes Yes acute phase response Risk of lung disease Very high High Low Normal Risk of liver

disease None High Low Normal >50% RNA editing >11 µM AAT Goal: Shift Pi*ZZ individuals to AAT biomarker profile consistent with Pi*MZ genotype 31

RNA editing aims to restore production of dynamic and therapeutically

relevant levels of AAT protein in Pi*ZZ individuals during acute phase response Lung damage occurs during exacerbations, when AAT protein has protective functions and is produced more AAT protein is needed for protection during acute phase response

30,9 10 00 0 900 30,100 Pi*MZ Pi*ZZ 30,8 00 00 0 30,8 00 00 0 700 700 CRP CRP 600 600 500 500 400 400 300 300 AAT protein AAT protein 200 200 100 100 0 0 0 7 14 21 0 7 14 21 Days Days Inflammatory stimulus Inflammatory stimulus RNA editing has

potential to restore dynamic AAT response to inflammation 32 Left: Mantovani A, Garlanda C. N Engl J Med, 2023;388:439-452; Right: Sanders et al., J COPD, 2018 Percent change in plasma concentration (%)

First-ever demonstration of ability to restore physiological serum AAT

production; total AAT reached 20.6 µM during acute phase response Pi*ZZ patients have a reduced capacity to produce AAT protein during an acute phase response 1 Following WVE-006 200 mg single dose, total AAT and M-AAT increased Published data

on CRP levels and AAT levels across different genotypes significantly in one patient during an acute phase response Total AAT Total AAT M-AAT M-AAT CRP 0 4 8 12 SAD MAD Acute phase response due to a kidney stone AAT response in Pi*ZZ participant

treated with WVE-006 mirrors Pi*MZ phenotype 33 1 - Sanders et al., J COPD, 2018 CRP: C-reactive protein Circulating M-AAT, Z-AAT, and total (M + Z) AAT protein in the serum were measured by highly selective and sensitive LC-MS/MS assays (LLOQ:

0.096 µM (M), 0.029 µM (Z)) and reported as mean participant SAD and MAD maximums M-AAT + Z-AAT (µM) CRP levels (mg/L)

WVE-006 enables endogenous AAT production during an acute phase

response while augmentation therapy may leave patients at risk Illustrative model of impact of acute phase response Augmentation therapy WVE-006 treatment approach Lung Protected damage lungs Endogenous AAT levels increase during acute phase

response without need for add’l doses Exogenous AAT levels are depleted before next scheduled IV dose IV dosing RNA editing dose • Augmentation therapy has no impact on liver disease• WVE-006 also reduces levels of Z-AAT WVE-006

therapeutic goal is to restore dynamic AAT physiology; augmentation therapy goal is to maximize AAT levels as dynamic response is not enabled 34 Serum AAT Serum AAT

CRP (mg/L) WVE-006 achieved key treatment goals of restoring MZ

phenotype Total AAT levels exceeded 11 µM, production of wild-type M-AAT of greater than 50%, restored physiological AAT production Plasma AAT of ~13 µM Wild-type M-AAT protein of 64% AAT reached >20 μM during an of total,

reduction in Z-AAT acute phase response • Protein levels associated with lower risk of AATD liver and lung diseases 400 mg single dose 12.8 µM total AAT 200 mg bi-weekly 11.9 µM total AAT Two weeks following single 200 mg dose 400 mg

monthly and 600 mg single dose data expected in May 2026 35 Circulating M-AAT, Z-AAT, and total (M + Z) AAT protein in the serum were measured by highly selective and sensitive LC-MS/MS assays (LLOQ: 0.096 µM (M), 0.029 µM (Z)) and

reported as mean participant SAD and MAD maximums. Middle: from 200 mg MAD cohort; Right: from 200 mg SAD cohort. Mutant Z-AAT Wild-type M-AAT

RestorAATion-2 clinical trial ongoing RestorAATion-1: Healthy

Volunteers RestorAATion-2: AATD Patients RestorAATion-1: Healthy Volunteers SAD → MAD Multi-dosing complete 600 mg SAD Cohort 3 MAD Cohort 3 600 mg 600 mg; Q4W 400 mg SAD Cohort 2 MAD Cohort 2 400 mg 400 mg; Q4W 200 mg SAD Cohort 1 MAD Cohort

1 100 mg 200 mg 200 mg Q2W 30 mg Study key objectives Safety and tolerability Pharmacokinetics Serum M-AAT levels 36 HV: healthy volunteer; SAD: single-ascending dose; MAD: multi-ascending dose

WVE-008 RNA editing (AIMer) PNPLA3 I148M liver disease 37

WVE-008 for PNPLA3 I148M liver disease GalNAc-RNA editing approach

uniquely aims to restore PNPLA3 function to fully address disease Homozygous PNPLA3 I148M carriers Heterozygous carriers have 80% lower risk of liver-related death as have significantly higher risk of compared to homozygous carriers 100 multiple

liver diseases Homozygous I148 MASH Heterozygous I148M MAFLD 98 HR = 1.70 (0.78–3.71) AIMer editing to 96 restore heterozygous phenotype 94 Homozygous I148M HR = 8.61 (3.28–22.60) 92 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 Years of

follow-up Over nine million homozygous PNPLA3 I148M patients with liver disease in US and Europe 38 1. Carlsson, B., et al. 2020 Aliment Pharmacol Ther.; 2. Unalp-Arida and Ruhl 2020 Hepatology; 3. Dong, XC, 2019 Front. Med. 4. Liver International,

2025; 45:e16133 MAFLD, Metabolic dysfunction-associated fatty liver disease; MASH, Metabolic dysfunction-associated steatohepatitis; ALD, alcoholic liver disease; AH, Alcohol-associated hepatitis; HCC, hepatocellular carcinoma Survival (%) of

liver-related death

Worsening Silencing of PNPLA3 in normal liver may worsen basal

physiological functions Silencing PNPLA3 increases Silencing PNPLA3 worsens steatosis in PNPLA3 siRNA exacerbates the fibrotic 1 2 iPSC-derived human liver organoids inflammation-induced liver cell death in response in hepatic stellate cells 3 human

primary hepatocytes UC I148M KO UC I148M KO Control OA Functional PNPLA3 is imperative for liver health beyond improvements in steatosis 39 1. Rady, B, et al. 2021 PLoS ONE 2021; 2. Hendriks, D, et al. 2023 Nat Biotechnol; 3. Tilson, SG, et al. 2021

Hepatology Worsening

RNA editing is expected to restore PNPLA3 function to treat across the

stages of liver diseases RNA editing approach ✓ PNPLA3 I148M aggravates steatosis Silencing PNPLA3 may only partially PNPLA3 correction expected to and fibrosis through gain-of-function address disease restore function, counter liver disease

ATGL PNPLA3 PNPLA3 I148M CGI-58 • Creates PNPLA3 loss of function • PNPLA3 I148M accumulates on LDs, • Restores full PNPLA3 activity • ATGL partial rescue for loss PNPLA3 sequesters CGI-58, inhibits ATGL’s lipase

• Restores lipid mobilization, reverses activity and lipid mobilization from ER • Silencing will not restore retinol metabolism steatosis, fibrosis, ballooning, and • Suppresses retinol metabolism in liver and inflammation •

Fibrosis, ballooning, and inflammation worsens inflammation and fibrosis persist • Promotes liver fat accumulation and fibrosis through activation of stellate cells 40 ATGL: adipose triglyceride lipase; CGI-58: co-factor for ATGL; ER

endoplasmic reticulum; LDs: lipid droplets; CGI-58 also called ABHD5 Liver International, 2025; 45:e16117; Human Molecular Genetics, (2014) 23(15): 4077–4085

AIMers achieve efficient editing of PNPLA3, leading to reduction of

liver fat ✱✱✱✱ Significant decrease in liver fat with PNPLA3 editing in human HEPATOPAC® model with homozygous I148M ns 1500 1000 500 PBS PNPLA3 PNPLA3 siRNA AIMer 0 Decrease in liver fat with WVE-008 in monolayer

model PNPLA3 siRNA PBS PNPLA3 siRNA WVE-008 41 One-way ANOVA with Dunnett post hoc test comparisons to Mock **** P< 0.0001 Mock PNPLA3 siRNA PNPLA3 AIMer 2 Lipid Droplet Density (pixel /cell) 2 Lipid Droplet Density (pixel /cell) % Lipid Droplet

Density vs. PBS (mean + SE) (mean + SE) (mean ± SE)

Preclinical data support WVE-008 as potential first-in-class, disease

modifying therapy, for treatment of PNPLA3 I148M liver disease Tissue exposure supports excellent Potent editing with WVE-008 Highly specific editing with WVE-008 delivery 1000 100 Semi-log scale 10 0 5 10 15 20 25 Time (day) Expect to file Clinical

Trial Application (CTA) for WVE-008 in 2026 42 Left: 4-parameter log-logistic dose response curve; Middle: Analysis utilized RNA-sequencing with two separate primary human hepatocyte cell lines (PH1/2). Variant calling utilized GATK best practices

for RNA variant calling using Mutect2 and display A->G evidence found when filtering for variants found in both cell lines and all doses. Liver Tissue Conc (μg/g)

Bifunctional modalities Single oligonucleotide constructs 43

Reimagining RNA medicines: Bifunctional modalities ✓ Engage both

endogenous Ago2 AGO2 and ADAR enzymes, as well as AGO2 dual RNAi silencing ✓ Silence multiple targets or silence Single one target while simultaneously Single Oligonucleotide Oligonucleotide editing or upregulating another Construct Construct

unique target ✓ Unlock complex indications that require engaging multiple targets ADAR AGO2 ✓ May continue to increase durability of editing 44 AIMer SpiNA SpiNA SpiNA

Other clinical programs Duchenne muscular dystrophy 45

Advancing WVE-N531 in exon 53 amenable DMD WVE-N531: exon skipping

oligonucleotide designed to induce production of endogenous, functional dystrophin protein • High unmet need for therapies delivering more consistent dystrophin expression, as few patients today achieve dystrophin >5% of normal •

Opportunity to extend dosing intervals beyond weekly standard of care to alleviate burden for patients and caregivers • Need to reach stem cells and distribute broadly to muscle tissues to potentially enable muscle regeneration and impact

respiratory and cardiac function • WVE-N531 has Rare Pediatric Disease Designation and Orphan Drug Designation from FDA DMD impacts ~1 / 5,000 newborn boys annually; ~20,000 new cases annually worldwide 46 Duan, D. et al. 2021 Nat Rev Dis

Primers 7, 13; Muscular Dystrophy Association; Aartsma-Rus, et al. 2009 Hum Mutat 30, 293.

FORWARD-53 48-week clinical trial results: WVE-N531’s potential

best-in- class profile for boys amenable to exon 53 skipping Statistically significant and clinically meaningful improvement (3.8s) in Time-to-Rise vs. ✓ natural history; functional benefits on other measures including NSAA Statistically

significant reductions in muscle fibrosis and CK; driven by decreases in ✓ inflammation and necrosis; transition from regenerative to mature muscle Consistent dystrophin expression averaged 7.8% between 24 and 48 weeks, with 88% of ✓

boys above 5% dystrophin; delivery to both myofibers and muscle stem cells WVE-N531 remains generally safe and well-tolerated with no Serious Adverse Events ✓ NDA filing for accelerated approval with monthly dosing planned for 2026 47 Muscle

content-adjusted dystrophin

Reimagining RNA medicines 48

Poised for significant and sustained growth driven by RNAi and RNA

editing Other hepatic targets Extra-hepatic targets RNAi WVE-007 Obesity SpiNA Bifunctional single oligonucleotide constructs RNA WVE-006 AATD Editing WVE-008 Other hepatic targets AIMers PNPLA3 I148M liver disease Extra-hepatic targets

Anticipated upcoming milestones • Deliver additional data from

INLIGHT, including data from the 600 mg SAD cohort in 2026 WVE-007 • Initiate Phase 2a multidose portion of INLIGHT in individuals living (INHBE) with obesity with higher BMI with and without type 2 diabetes in 2Q 2026 Obesity •

Combination and maintenance studies of WVE-007 expected to initiate in 2026 • Deliver data from 400 mg MAD cohort and 600 mg SAD cohort in May 2026 WVE-006 • Deliver multidose data from 600 mg cohort in 2H 2026 (SERPINA1) •

Regulatory feedback on potential accelerated approval pathway expected mid-2026 AATD WVE-008 • File CTA for WVE-008 in 2026 PNPLA3 I148M liver disease WVE-N531 • Submit NDA to support accelerated approval of WVE-N531 with monthly dosing

in 2026 (exon 53) DMD 50 BMI: body mass index AATD: alpha-1 antitrypsin deficiency DMD: Duchenne muscular dystrophy CTA: Clinical Trial Application NDA: New Drug Application.

For questions contact: investorrelations@wavelifesci.com

GRAPHIC

Filename: g135689ex99_1p10g1.jpg · Sequence: 7

Binary file (267084 bytes)

Download g135689ex99_1p10g1.jpg

GRAPHIC

Filename: g135689ex99_1p11g1.jpg · Sequence: 8

Binary file (208773 bytes)

Download g135689ex99_1p11g1.jpg

GRAPHIC

Filename: g135689ex99_1p12g1.jpg · Sequence: 9

Binary file (161482 bytes)

Download g135689ex99_1p12g1.jpg

GRAPHIC

Filename: g135689ex99_1p13g1.jpg · Sequence: 10

Binary file (275907 bytes)

Download g135689ex99_1p13g1.jpg

GRAPHIC

Filename: g135689ex99_1p14g1.jpg · Sequence: 11

Binary file (238312 bytes)

Download g135689ex99_1p14g1.jpg

GRAPHIC

Filename: g135689ex99_1p15g1.jpg · Sequence: 12

Binary file (269766 bytes)

Download g135689ex99_1p15g1.jpg

GRAPHIC

Filename: g135689ex99_1p16g1.jpg · Sequence: 13

Binary file (279313 bytes)

Download g135689ex99_1p16g1.jpg

GRAPHIC

Filename: g135689ex99_1p17g1.jpg · Sequence: 14

Binary file (213478 bytes)

Download g135689ex99_1p17g1.jpg

GRAPHIC

Filename: g135689ex99_1p18g1.jpg · Sequence: 15

Binary file (250414 bytes)

Download g135689ex99_1p18g1.jpg

GRAPHIC

Filename: g135689ex99_1p19g1.jpg · Sequence: 16

Binary file (226892 bytes)

Download g135689ex99_1p19g1.jpg

GRAPHIC

Filename: g135689ex99_1p20g1.jpg · Sequence: 17

Binary file (278744 bytes)

Download g135689ex99_1p20g1.jpg

GRAPHIC

Filename: g135689ex99_1p21g1.jpg · Sequence: 18

Binary file (289021 bytes)

Download g135689ex99_1p21g1.jpg

GRAPHIC

Filename: g135689ex99_1p22g1.jpg · Sequence: 19

Binary file (313203 bytes)

Download g135689ex99_1p22g1.jpg

GRAPHIC

Filename: g135689ex99_1p23g1.jpg · Sequence: 20

Binary file (286646 bytes)

Download g135689ex99_1p23g1.jpg

GRAPHIC

Filename: g135689ex99_1p24g1.jpg · Sequence: 21

Binary file (294797 bytes)

Download g135689ex99_1p24g1.jpg

GRAPHIC

Filename: g135689ex99_1p25g1.jpg · Sequence: 22

Binary file (240808 bytes)

Download g135689ex99_1p25g1.jpg

GRAPHIC

Filename: g135689ex99_1p26g1.jpg · Sequence: 23

Binary file (219519 bytes)

Download g135689ex99_1p26g1.jpg

GRAPHIC

Filename: g135689ex99_1p27g1.jpg · Sequence: 24

Binary file (141070 bytes)

Download g135689ex99_1p27g1.jpg

GRAPHIC

Filename: g135689ex99_1p28g1.jpg · Sequence: 25

Binary file (169925 bytes)

Download g135689ex99_1p28g1.jpg

GRAPHIC

Filename: g135689ex99_1p29g1.jpg · Sequence: 26

Binary file (296995 bytes)

Download g135689ex99_1p29g1.jpg

GRAPHIC

Filename: g135689ex99_1p2g1.jpg · Sequence: 27

Binary file (371440 bytes)

Download g135689ex99_1p2g1.jpg

GRAPHIC

Filename: g135689ex99_1p30g1.jpg · Sequence: 28

Binary file (267955 bytes)

Download g135689ex99_1p30g1.jpg

GRAPHIC

Filename: g135689ex99_1p31g1.jpg · Sequence: 29

Binary file (188216 bytes)

Download g135689ex99_1p31g1.jpg

GRAPHIC

Filename: g135689ex99_1p32g1.jpg · Sequence: 30

Binary file (279666 bytes)

Download g135689ex99_1p32g1.jpg

GRAPHIC

Filename: g135689ex99_1p33g1.jpg · Sequence: 31

Binary file (291696 bytes)

Download g135689ex99_1p33g1.jpg

GRAPHIC

Filename: g135689ex99_1p34g1.jpg · Sequence: 32

Binary file (237061 bytes)

Download g135689ex99_1p34g1.jpg

GRAPHIC

Filename: g135689ex99_1p35g1.jpg · Sequence: 33

Binary file (268097 bytes)

Download g135689ex99_1p35g1.jpg

GRAPHIC

Filename: g135689ex99_1p36g1.jpg · Sequence: 34

Binary file (182795 bytes)

Download g135689ex99_1p36g1.jpg

GRAPHIC

Filename: g135689ex99_1p37g1.jpg · Sequence: 35

Binary file (148333 bytes)

Download g135689ex99_1p37g1.jpg

GRAPHIC

Filename: g135689ex99_1p38g1.jpg · Sequence: 36

Binary file (239880 bytes)

Download g135689ex99_1p38g1.jpg

GRAPHIC

Filename: g135689ex99_1p39g1.jpg · Sequence: 37

Binary file (239316 bytes)

Download g135689ex99_1p39g1.jpg

GRAPHIC

Filename: g135689ex99_1p3g1.jpg · Sequence: 38

Binary file (296891 bytes)

Download g135689ex99_1p3g1.jpg

GRAPHIC

Filename: g135689ex99_1p40g1.jpg · Sequence: 39

Binary file (299354 bytes)

Download g135689ex99_1p40g1.jpg

GRAPHIC

Filename: g135689ex99_1p41g1.jpg · Sequence: 40

Binary file (276459 bytes)

Download g135689ex99_1p41g1.jpg

GRAPHIC

Filename: g135689ex99_1p42g1.jpg · Sequence: 41

Binary file (198940 bytes)

Download g135689ex99_1p42g1.jpg

GRAPHIC

Filename: g135689ex99_1p43g1.jpg · Sequence: 42

Binary file (164548 bytes)

Download g135689ex99_1p43g1.jpg

GRAPHIC

Filename: g135689ex99_1p44g1.jpg · Sequence: 43

Binary file (242688 bytes)

Download g135689ex99_1p44g1.jpg

GRAPHIC

Filename: g135689ex99_1p45g1.jpg · Sequence: 44

Binary file (150448 bytes)

Download g135689ex99_1p45g1.jpg

GRAPHIC

Filename: g135689ex99_1p46g1.jpg · Sequence: 45

Binary file (292110 bytes)

Download g135689ex99_1p46g1.jpg

GRAPHIC

Filename: g135689ex99_1p47g1.jpg · Sequence: 46

Binary file (293591 bytes)

Download g135689ex99_1p47g1.jpg

GRAPHIC

Filename: g135689ex99_1p48g1.jpg · Sequence: 47

Binary file (154334 bytes)

Download g135689ex99_1p48g1.jpg

GRAPHIC

Filename: g135689ex99_1p49g1.jpg · Sequence: 48

Binary file (211533 bytes)

Download g135689ex99_1p49g1.jpg

GRAPHIC

Filename: g135689ex99_1p4g1.jpg · Sequence: 49

Binary file (253001 bytes)

Download g135689ex99_1p4g1.jpg

GRAPHIC

Filename: g135689ex99_1p50g1.jpg · Sequence: 50

Binary file (233960 bytes)

Download g135689ex99_1p50g1.jpg

GRAPHIC

Filename: g135689ex99_1p51g1.jpg · Sequence: 51

Binary file (183225 bytes)

Download g135689ex99_1p51g1.jpg

GRAPHIC

Filename: g135689ex99_1p5g1.jpg · Sequence: 52

Binary file (264397 bytes)

Download g135689ex99_1p5g1.jpg

GRAPHIC

Filename: g135689ex99_1p6g1.jpg · Sequence: 53

Binary file (199511 bytes)

Download g135689ex99_1p6g1.jpg

GRAPHIC

Filename: g135689ex99_1p7g1.jpg · Sequence: 54

Binary file (143033 bytes)

Download g135689ex99_1p7g1.jpg

GRAPHIC

Filename: g135689ex99_1p8g1.jpg · Sequence: 55

Binary file (307884 bytes)

Download g135689ex99_1p8g1.jpg

GRAPHIC

Filename: g135689ex99_1p9g1.jpg · Sequence: 56

Binary file (240921 bytes)

Download g135689ex99_1p9g1.jpg

GRAPHIC

Filename: g135689ex99_2p1g1.jpg · Sequence: 57

Binary file (299953 bytes)

Download g135689ex99_2p1g1.jpg

GRAPHIC

Filename: g135689g0428082216300.jpg · Sequence: 58

Binary file (5867 bytes)

Download g135689g0428082216300.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 60

v3.26.1

Document and Entity Information

Apr. 28, 2026

Cover [Abstract]

Entity Address, Address Line One

7 Straits View #12-00

Amendment Flag

false

Entity Central Index Key

0001631574

Document Type

8-K

Document Period End Date

Apr. 28, 2026

Entity Registrant Name

WAVE LIFE SCIENCES LTD.

Entity Incorporation State Country Code

Entity File Number

001-37627

Entity Tax Identification Number

98-1356880

Entity Address, Address Line Two

Marina One

Entity Address, City or Town

East Tower

Entity Address, Country

Entity Address, Postal Zip Code

018936

City Area Code

Local Phone Number

6236 3388

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Security 12b Title

$0 Par Value Ordinary Shares

Trading Symbol

WVE

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration